Enzon Finalizes Terms for Merger with Viskase, Confirming 1-for-100 Reverse Split and Significant Dilution

summarizeSummary

Enzon Pharmaceuticals filed the definitive prospectus for its merger with Viskase, detailing the 1-for-100 reverse stock split and the exchange offer for Series C Preferred Stock, which will result in legacy Enzon common stockholders owning approximately 5% of the combined company.

check_boxKey Events

• Merger Finalized

  Enzon will merge with Viskase, with Viskase becoming a wholly-owned subsidiary. The combined entity will be renamed "Viskase Holdings, Inc." and its common stock will be quoted on OTCQB.

• Significant Dilution for Existing Shareholders

  Legacy Enzon common stockholders are expected to own approximately 5% of the combined company's common stock post-merger, representing a substantial reduction in their equity and voting power.

• Reverse Stock Split Confirmed

  A 1-for-100 reverse stock split will be effected immediately prior to the merger, reducing the number of outstanding common shares.

• Preferred Stock Exchange Offer

  Enzon will offer to exchange its Series C Preferred Stock for common stock, with the IEH Parties converting their 98.2% stake and other holders offered the same terms, based on the adjusted volume-weighted average price of $7.83 per share.

auto_awesomeAnalysis

This definitive prospectus (424B3) finalizes the terms of the previously announced merger with Viskase, confirming a highly dilutive outcome for existing Enzon common stockholders. The transaction involves a 1-for-100 reverse stock split and an exchange of Series C Preferred Stock for common stock, leading to legacy Enzon common stockholders retaining only about 5% ownership in the newly formed "Viskase Holdings, Inc." This represents a significant loss of equity and voting power. Furthermore, the merger consolidates control under Icahn Enterprises Holdings L.P. (IEH Parties), who will own approximately 93.32% of the combined company. While the merger provides a solution to Viskase's stated "substantial doubt" about its ability to continue as a going concern, the terms are overwhelmingly unfavorable for non-IEH Enzon shareholders, fundamentally altering their investment thesis. Investors should be aware of the drastic change in ownership structure and control.